Source MS Trust: The MS Trust has praised the pioneering work of the MS Risk Sharing Scheme (RSS) as the final results from the scheme are published in the BMJ today (September 24).
“The RSS was a truly innovative scheme and continues to deliver real benefits for people with MS,” commented David Martin, Chief Executive of the MS Trust. “Not only has the scheme enabled over 18,000 people with MS to access disease-modifying treatments (DMTs), but it has also been the catalyst for the development of MS services, completely transforming the landscape for the 110,000 people living with MS across the UK.
“As administrator of the scheme, we are proud to have contributed to what has been achieved, but we won’t be resting on our laurels. People with MS still face many challenges and we will continue to fight to ensure everyone has access to the best possible treatments and MS services, now and in the future.”
The MS Risk Sharing Scheme was a unique partnership – the first of its kind in the UK – which enabled people with MS to access the original four disease-modifying therapies (Avonex, Betaferon, Copaxone and Rebif) on the NHS. Read on.